Evolus (NASDAQ:EOLS) Receives “Buy” Rating from HC Wainwright

Evolus (NASDAQ:EOLS)‘s stock had its “buy” rating restated by HC Wainwright in a report issued on Friday,Benzinga reports. They presently have a $20.00 price target on the stock. HC Wainwright’s price target indicates a potential upside of 262.98% from the company’s current price.

Several other brokerages have also recently commented on EOLS. Wall Street Zen upgraded shares of Evolus from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. Needham & Company LLC reaffirmed a “hold” rating on shares of Evolus in a report on Wednesday, December 24th. Weiss Ratings reissued a “sell (e+)” rating on shares of Evolus in a research note on Monday, December 22nd. Finally, Mizuho dropped their price objective on Evolus from $20.00 to $19.00 and set an “outperform” rating for the company in a report on Monday, December 1st. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Evolus currently has a consensus rating of “Moderate Buy” and a consensus price target of $20.80.

Evolus Price Performance

Shares of EOLS stock traded down $0.23 on Friday, reaching $5.51. 2,183,621 shares of the stock were exchanged, compared to its average volume of 1,368,922. Evolus has a one year low of $5.13 and a one year high of $17.12. The stock has a market cap of $357.16 million, a PE ratio of -5.99 and a beta of 0.91. The stock has a 50 day moving average price of $6.81 and a 200 day moving average price of $7.33.

Evolus (NASDAQ:EOLS) last announced its quarterly earnings data on Wednesday, November 5th. The company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.05. The firm had revenue of $68.97 million during the quarter, compared to analyst estimates of $91.23 million. On average, research analysts expect that Evolus will post -0.61 earnings per share for the current fiscal year.

Insider Activity at Evolus

In other news, insider David Moatazedi sold 10,539 shares of the firm’s stock in a transaction dated Monday, December 22nd. The stock was sold at an average price of $7.15, for a total transaction of $75,353.85. Following the sale, the insider owned 354,388 shares of the company’s stock, valued at $2,533,874.20. This trade represents a 2.89% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 5.90% of the stock is currently owned by corporate insiders.

Institutional Trading of Evolus

Large investors have recently bought and sold shares of the business. Frazier Life Sciences Management L.P. acquired a new stake in Evolus during the 2nd quarter worth approximately $22,431,000. Nantahala Capital Management LLC raised its holdings in shares of Evolus by 33.2% during the third quarter. Nantahala Capital Management LLC now owns 5,726,857 shares of the company’s stock worth $35,163,000 after acquiring an additional 1,428,931 shares during the period. Soleus Capital Management L.P. raised its holdings in shares of Evolus by 96.4% during the second quarter. Soleus Capital Management L.P. now owns 2,119,000 shares of the company’s stock worth $19,516,000 after acquiring an additional 1,039,842 shares during the period. Caligan Partners LP lifted its position in Evolus by 23.8% in the 3rd quarter. Caligan Partners LP now owns 4,138,943 shares of the company’s stock valued at $25,413,000 after acquiring an additional 796,973 shares in the last quarter. Finally, Pinnacle Associates Ltd. acquired a new position in Evolus in the 2nd quarter worth $6,318,000. 90.69% of the stock is owned by institutional investors.

About Evolus

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.